177Lu-PSMA-0057

N/A

Report date: 2025/11/26 20:00:44

NME

Base Information

Drug Name177Lu-PSMA-0057

Drug Alias Name177Lu-PSMA-0057

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionPositron-emission tomography enhancersProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesNanjing First Hospital, Nanjing Medical University

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Ruihe Pharmaceutical Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A